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Background: Evidence of the association of metabolic syndrome (MetS) with cancer risk is accumulating. However,
uncertainties still exist as to the link of MetS with bladder cancer. This study aimed to assess the relationship
between MetS and the risk of urothelial carcinoma of the bladder (UC) in a Chinese population.
Methods: We retrospectively analyzed clinicopathological data of 972 newly diagnosed UC patients and 1098
cancer-free controls matched to the cases by age and gender. Odds ratios (ORs) and 95 % confidence intervals (CIs)
were calculated using unconditional logistic regression in both unadjusted and adjusted models.
Results: MetS was not significantly associated with the overall UC risk (p = 0.08). However, a significant association
of MetS with UC was observed in female patients (p = 0.006). Diabetes mellitus (crude OR 1.339, 95 % CI 1.079–1.662,
p = 0.008; adjusted OR 1.767, 95 % CI 1.308–2.386, p < 0.001) and hypertriglyceridemia (crude OR 1.245, 95 % CI
1.018–1.522, p = 0.033; adjusted OR 1.254, 95 % CI 1.020–1.542, p = 0.032) were significantly associated with UC
risk. As the number of MetS components increased, the UC risk was elevated. Having three or more (versus zero)
components of MetS was significantly related to risk of overall UC (OR 1.315; 95 % CI 1.006–1.719; p = 0.045) and
non-muscle invasive bladder cancer (OR 1.354; 95 % CI 1.019–1.798; p = 0.037).
Conclusions: The present study indicated a marginal association between MetS and UC risk, and a significant
association with UC risk in female patients. The results need to be evaluated in large-scale prospective cohorts.
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EpidemiologyBackground
Urothelial carcinoma of the bladder (UC) is the most
common malignancy of the urinary tract, ranking fourth
in incidence in Western countries and first in China [1].
Both inherited and environmental factors, such
as smoking, contact with aromatic amine compounds,
and human papillomavirus infection, play vital roles in* Correspondence: zj9488@163.com; slijiang999@126.com
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well-established risk factors cannot fully illuminate
the comprehensive mechanisms of UC initiation and
development.
Metabolic syndrome (MetS), a cluster of abnormal
metabolic factors related to excess calorie intake and
sedentary lifestyles, has become a global health issue
with growing prevalence [5]. To date, different organiza-
tions have introduced several criteria for MetS, all of
which are based on insulin resistance, a quantificational
index that cannot be easily measured. MetS mostly
features [6] obesity, diabetes mellitus, hypertension, and
dyslipidemia, and is considered an important risk factoristributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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of a relationship between MetS and the risk of cancer is
accumulating in diseases such as colorectal cancer,
breast cancer, lung cancer, prostate cancer, and renal cell
carcinoma [8–12]. However, only a few studies [13, 14]
have examined the association of MetS with UC and
drawn conflicting conclusions. A weak significant asso-
ciation was found between MetS and UC risk in men in
Esposito’s [12] study. However, Cantiello et al. [15]
found that MetS did not represent an independent risk
factor in UC. Given the relative scarcity and inconsist-
ency of existing data, our intention is to provide add-




We gathered the data of 972 patients with newly diag-
nosed, pathologically confirmed UC at the Department of
Urology at the Affiliated Hospital of Qingdao University
from June 2011 to March 2014 and at the Department of
Urology at the Second Affiliated Hospital of Xi’an Jiaotong
University from January 2013 to March 2014. Patients
with non-urothelial carcinoma of bladder were excluded
from the study. In addition, for patients who were re-
admitted to the hospital due to tumor recurrence and/or
distant metastasis, only the information of first admission
was included. We recruited 1098 cancer-free controls
that sought routine health checkups from June 2011 to
March 2014 from the Affiliated Hospital of Qingdao
University. They were matched to the cases by age and
gender. Data on age, gender, diseases and medication his-
tory (hypertension, diabetes), smoking status, alcohol con-
sumption, anthropometric measurements (weight, height),
blood tests (circulating levels of glucose and lipid profiles),
stage at diagnosis (TNM classification), and pathology
grade were collected from medical records. The institu-
tional research review boards of the two clinical centers
approved our study protocols, and signed informed
consent was obtained from all the participants.
Exposure measures
Age, gender, smoking status, alcohol consumption, and
MetS were introduced as risk factors. MetS is defined
according to the standard of the Chinese Diabetes
Society [16], which sets three of five of the following cri-
teria as necessary: (1) overweight, defined as body mass
index (BMI) ≥25 kg/m2; (2) hypertension, a self-report
of a physician’s diagnosis of hypertension, or over 140
and 90 mmHg for systolic and diastolic blood pressure,
respectively, on three consecutive occasions; (3)
diabetes, defined as meeting any one of the following:
elevated fasting glucose ≥7.0 mmol/L, use of drugs
to retain a normal serum glucose level, or physician’sdiagnosis; and (4) abnormal triglyceride (TG) or high-
density lipoprotein (HDL) levels: hypertriglyceridemia, a
serum TG level ≥150 mg/dL (1.7 mmol/L); and low HDL-
cholesterol, defined as <40 mg/dL (1.03 mmol/L) (male)
or <50 mg/dL (1. 3 mmol/L) (female).
Statistical analyses
Statistical analyses were performed using SPSS 19.0
software (IBM Corporation, Somers, NY, USA). A p value
<0.05 (two-tailed) was defined as statistically significant.
To assess the differences among the dichotomous categor-
ical variables, including overweight, smoking status (no or
ever/current), alcohol consumption (no or yes), hyperten-
sion (no or yes), diabetes (no or yes), triglycerides (normal
or abnormal), HDL (normal or abnormal), and MetS (no
or yes), chi-squared tests were used. Crude and adjusted
odds ratios (ORs) and 95 % confidence intervals (CIs)
were estimated using logistic regression analysis models.
Results
Of 972 UC cases and 1098 controls included in our study,
the cases had a median age of 62 years and the controls
had a median age of 63 years. No statistical significance
was found in age, gender, alcohol consumption, or MetS
between groups (Table 1). Smoking status was statistically
associated with an elevated UC risk.
To further evaluate the link between individual compo-
nents of MetS and UC risk, using univariate and multi-
variate logistic regression models, we found that diabetes
(crude OR 1.339, 95 % CI 1.079–1.662; adjusted OR 1.767,
95 % CI 1.308–2.386) and hypertriglyceridemia (crude OR
1.245,95 % CI 1.018–1.522; adjusted OR 1.254, 95 % CI
1.020–1.542) were significantly related to UC risk. How-
ever, no association was observed between overweight,
hypertension, or abnormal HDL levels and UC (Table 2).
Table 3 lists crude and adjusted ORs and 95 % CIs for
overall UC risk, non-muscle invasive bladder cancer
(NMIBC) risk, and invasive bladder cancer (IBC) risk
according to the number of MetS components. There
appeared to be a biologic gradient between the number
of MetS components and the risk of UC. An increasing
number of MetS components was associated with a
higher probability of UC, NMIBC, and IBC diagnoses.
In multivariate logistic regression analyses, having one
component or two components of MetS (versus zero)
was not related to an increased risk of overall UC,
NMIBC, or IBC. However, having three or more (versus
zero) components of MetS was significantly associated
with a risk of overall UC (OR 1.315; 95 % CI 1.006–1.719;
p = 0.045) and NMIBC (OR 1.354; 95 % CI 1.019–1.798;
p = 0.037), but not IBC (OR 1.196; 95 % CI 0.744–1.924;
p = 0.459).
We next analyzed the association of MetS, diabetes,
and hypertriglyceridemia with UC risk in male and
Table 1 Demographic and clinical characteristics of 972 UC cases and 1098 controls
Variables Controls, n (%) UC cases, n (%) P value
Age, years 0.559
<45 111 (10.1) 86 (8.8)
45- 196 (17.9) 159 (16.4)
55- 314 (28.6) 289 (29.7)
≥65 477 (43.4) 438 (45.1)
Median (IQR) 62 (19) 63 (20)
Gender 0.906
Male 914 (83.2) 811 (83.4)
Female 184 (16.8) 161 (16.6)
BMI, kg/m2 0.425
<25 610 (55.6) 523 (53.8)
≥25 488 (44.4) 449 (46.2)
Smoking status 0.005
No 697 (63.5) 558 (57.4)
Ever/current 401 (36.5) 414 (42.6)
Alcohol consumption 0.861
No 745 (67.9) 656 (67.5)
Yes 353 (32.1) 316 (32.5)
Hypertension 0.506
No 775 (70.6) 673 (69.2)
Yes 323 (29.4) 299 (30.8)
Diabetes mellitus 0.008
No 903 (82.2) 754 (77.6)
Yes 195 (17.8) 218 (22.4)
Lipid profiles, mg/dL
Triglycerides 0.033
Normal (<150) 852 (77.6) 715 (73.6)
Abnormal(≥150) 246 (22.4) 257 (26.4)
HDL 0.158
Normal(≥40) 890 (81.1) 811 (83.4)
Abnormal(<40) 208 (18.9) 161 (16.6)
MetS 0.080
No 938 (85.4) 803 (82.6)
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aUC urothelial carcinoma of bladder; BMI body mass index; LGMPUP low-grade malignant papillary urothelial papilloma; LGPUC low-grade papillary urothelial
carcinoma; HGPUC high-grade papillary urothelial carcinoma
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associated with increased UC risk (crude p = 0.006,
adjusted p = 0.009); however, there were no statistically
significant differences in male patients (Table 4). Neither
diabetes nor hypertriglyceridemia was an independent risk
factor of UC in female patients; Hypertriglyceridemia was
an independent risk factor of UC only in male patients
(Table 5).
Discussion
In our retrospective study, a notable association of MetS
with UC risk in female patients was observed. Diabetes
and hypertriglyceridemia were prevalent in UC patients in
comparison with the controls, and hypertriglyceridemia
was significantly associated with increased UC risk in male
patients. In addition, with an increasing number of com-
ponents of the MetS, the risk of overall UC, NMIBC, and
IBC was elevated.
Although previous studies have shown a significant
association of MetS with some common cancers [8–12], a
few studies have focused on the relationship between
MetS and UC. Recently, Esposito et al. [12] found a weakly
significant association (p = 0.013) between MetS and the
risk of UC in men. Moreover, Ozbek et al. [14] showed
that patients with MetS had a significantly higher T stage
and grade of UC. Nevertheless, Cantiello et al. [15]
reported that MetS did not represent an independent risk
factor in UC. In our study, there was no significant differ-
ence between MetS and the risk of UC in men, yet a
significant association between MetS and UC risk was
found in women. The discrepancies might be caused by
the differences in race of the study participants and our
relatively small sample sizes in female patients. Further-
more, the definition of MetS and pharmaceutical treat-
ment and lifestyle modifications are different comparedTable 2 Logistic regression analysis of factors possibly related to UC
Factors Overweight Hypertension
Controls, n (%) 488 (52.1) 323 (51.9)
UC cases, n (%) 449 (47.9) 299 (48.1)
P value 0.425 0.506
Crude OR (95 % CI) 1.073 (0.902–1.276) 1.066 (0.883–1.287)
Adjusteda P value 0.456 0.577
Adjusteda OR (95 % CI) 0.925 (0.754–1.135) 1.057 (0.871–1.282)
aAdjusted for age (continuous), smoking status, gender, BMI (continuous), hypertenwith those in developed Western societies. In our study,
the database included only a Chinese population, and the
results may not be generalized to other ethnic groups. As
we know, incidence of MetS varies widely across popula-
tions. Some factors, such as gender and race, can influence
the prevalence of MetS. Hence, further studies based on a
large-scale population are warranted.
Wallner et al. [17] indicated that analyzing MetS as a
single condition may be inadequate for uniting all the
multiple MetS components to a single variable, which
may confuse or obscure the independent impacts and
interactions of each individual metabolic component on
cancer. Therefore, we investigated each single compo-
nent of MetS and the association with UC risk. Holick
et al. [18] and Haggstrom et al. [13] found no association
of overweight with UC. Conversely, Koebnick et al. [19]
indicated that overweight was related to increased UC
risk. Another two research groups [15, 20] found that
UC patients with higher BMI had worse tumor charac-
teristics. Interestingly, Goldbohm et al. [21] reported
that overweight was a protective factor for UC. The
relationship of hypertension with UC risk was likewise
inconsistent. A Japanese case-control study [22] reported
a lower risk of UC in men with hypertension. However,
Haggstrom et al. [13] reported that higher blood pressure
was consistently related to higher UC risk. In our study,
both overweight and hypertension were not related to
increased UC risk. In addition, diabetes was observed as
an independent risk factor for UC in our study, which was
in agreement with previous studies. Recently, a cohort
research [23, 24] reported a significant association of
diabetes with increased risk of bladder cancer, without
distinguishing the gender. A meta-analysis conducted by
Larsson et al. [25] demonstrated that high glucose levels
were prevalent in UC patients. Research on the link ofrisk
Diabetes Hypertriglyceridemia Low-HDL-cholesterol
195 (47.2) 246 (48.9) 208 (56.4)
218 (52.8) 257 (51.1) 161 (43.6)
0.008 0.033 0.158
1.339 (1.079–1.662) 1.245 (1.018–1.522) 0.849 (0.677–1.066)
0.000 0.032 0.085
1.767 (1.308–2.386) 1.254 (1.020–1.542) 0.789 (0.626–1.119)
sion, diabetes mellitus, hypertriglyceridemia, low HDL-cholesterol
Table 3 Logistic regression analysis of the number of cumulative MetS components and overall UC risk, non-muscle invasive
bladder cancer (NMIBC) risk, and invasive bladder cancer (IBC) risk
Number of metabolic risk factors Dichotomously defined
0 components 1 component 2 components ≥3 components MetS No MetS
Overall UC Controls (n) 355 (55.1) 363 (53.6) 220 (52.4) 160 (48.6)
UC cases (n) 289 (44.9) 314 (46.4) 200 (47.6) 169 (51.4)
P value Ref 0.583 0.380 0.055
Crude OR (95 % CI) Ref 1.063 (0.856–1.320) 1.117 (0.873–1.429) 1.297 (0.994–1.693)
Adjusteda P value Ref 0.537 0.398 0.045
Adjusteda OR (95 % CI) Ref 1.071 (0.862–1.331) 1.113 (0.869–1.425) 1.315 (1.006–1.719)
NMIBC Controls (n) 355 (60.9) 363 (57.9) 220 (56.3) 160 (53.7) 160 (53.7) 938 (58.6)
UC cases (n) 228 (39.1) 264 (42.1) 171 (43.7) 138 (46.3) 138 (46.3) 663 (41.4)
P value Ref 0.289 0.150 0.040 0.116 Ref
Crude OR (95 % CI) Ref 1.132 (0.900–1.425) 1.210 (0.933–1.570) 1.343 (1.013–1.780) 1.220 (0.952–1.564) Ref
Adjusteda P value Ref 0.264 0.169 0.037 0.107 Ref
Adjusteda OR (95 % CI) Ref 1.140 (0.906–1.436) 1.201 (0.925–1.559) 1.354 (1.019–1.798) 1.228 (0.957–1.577) Ref
IBC Controls (n) 355 (85.3) 363 (87.9) 220 (88.4) 160 (83.8) 160 (83.8) 938 (87.0)
UC cases (n) 61 (14.7) 50 (12.1) 29 (11.6) 31 (16.2) 31 (16.2) 140 (13.0)
P value Ref 0.280 0.272 0.617 0.227 Ref
Crude OR (95 % CI) Ref 0.802 (0.537–1.198) 0.767 (0.478–1.231) 1.128 (0.704–1.806) 1.298 (0.850–1.983) Ref
Adjusteda P value Ref 0.362 0.309 0.459 0.162 Ref
Adjusteda OR (95 % CI) Ref 0.829 (0.553–1.241) 0.781 (0.485–1.257) 1.196 (0.744–1.924) 1.356 (0.885–2.077) Ref
MetS metabolic syndrome; UC urothelial carcinoma of bladder; NMIBC non-muscle invasive bladder cancer; IBC invasive bladder cancer
aAdjusted for age (continuous), smoking status, gender
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study, there was no significant association between serum
levels of cholesterol and TG and UC risk. However, the
study conducted by Schatzkin et al. [26] showed an inverse
association between cholesterol levels and UC. Our results
showed that hypertriglyceridemia was an independent risk
factor for UC risk in the total and male patients.Table 4 Logistic regression analysis of association of MetS and UC r
Male Controls, n (%)
UC cases, n (%)
P value
Crude OR (95 % CI)
Adjusteda P value
Adjusteda OR (95 % CI)
Female Controls, n (%)
UC cases, n (%)
P value
Crude OR (95 % CI)
Adjusteda P value
Adjusteda OR (95 % CI)
aAdjusted for age (continuous), smoking statusMetS was most commonly analyzed in a binary manner
in previous studies, which neglected the spectrum of the
severity of metabolic abnormalities. For the first time, we
investigated the number of cumulative MetS components
and UC risk to determine a biological gradient for the re-
lationship of MetS with UC. We found that as the number
of MetS components increased, the UC risk was elevatedisk in male and female patients
MetS
Yes No
134 (14.7) 780 (85.3)





26 (14.1) 158 (85.9)





Table 5 Logistic regression analysis of association of diabetes mellitus, triglycerides and UC risk in male and female patients
Gender Diabetes mellitus Triglycerides
Yes No Yes No
Male Controls, n (%) 168 (18.4) 746 (81.6) 190 (20.8) 724 (79.2)
UC cases, n (%) 174 (21.5) 637 (78.5) 202 (24.9) 609 (75.1)
p value 0.110 Ref 0.042 Ref
Crude OR (95 % CI) 1.213 (0.957–1.537) Ref 1.264 (1.009–1.584) Ref
Adjusteda p value 0.001 Ref 0.038 Ref
Adjusteda OR (95 % CI) 1.757 (1.268–2.434) Ref 1.276 (1.014–1.604) Ref
Female Controls, n (%) 27 (14.7) 157 (85.3) 56 (30.4) 128 (69.6)
UC cases, n (%) 44 (27.3) 117 (72.7) 55 (34.2) 106 (65.8)
p value 0.004 Ref 0.460 Ref
Crude OR (95 % CI) 2.187 (1.280–3.736) Ref 1.186 (0.754–1.865) Ref
Adjusteda p value 0.08 Ref 0.593 Ref
Adjusteda OR (95 % CI) 2.032 (0.918–4.500) Ref 1.145 (0.697–1.880) Ref
aAdjusted for age (continuous), smoking status, BMI (continuous), hypertension, diabetes mellitus, hypertriglyceridemia, low HDL-cholesterol
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with those with none of the risk factors of MetS, MetS is
more common in NMIBC patients.
The mechanisms responsible for the association of
MetS with UC are not fully clear. Some studies have in-
dicated the interactions we studied, while the signaling
pathways remain unknown. One possible explanation is
that the incidence of urinary tract infections is remark-
ably increased among diabetic subjects, particularly in
women, which was considered a risk factor contributing
to UC carcinogenesis [27]. Insulin resistance and chronic
inflammation are also culprits in the link between obesity
and UC [28].
Our study also implicates another clinical factor. It is
well known that MetS conveys a pivotal contribution to
an increased CAD risk, which remains a leading cause
of health impairment [7, 29]. Because MetS plays an
important role in CAD, and possibly in UC development,
we believe that a deeper understanding of the underlying
mechanisms and better control of MetS may obtain more
and unexpected benefits.
Our study has several limitations. Although we adjusted
for many possible confounders, we did not adjust for
other possible residual confounders, such as physical
activity and dietary factors. Likewise, information includ-
ing the duration and treatment of MetS, which may theor-
etically influence the natural development of UC, was
also lacking. In addition, our study was retrospective,
which introduces an intrinsic selection bias. This retro-
spective design only allowed us to examine the temporal
relationship between MetS and UC; thereby, causal infer-
ences are limited. Clearly, prospective larger-scale studies
are needed.Conclusions
MetS was significantly associated with a risk of UC
in female patients. Diabetes and hypertriglyceridemia
were independent UC risk factors for UC risk.
Furthermore, as the number of MetS components
increased, the risk of overall UC, NMIBC, and IBC
was elevated.
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